A Drug Half as Good as Ozempic for One-30th the Price

theatlantic.com

I like this article but it misses a major point.

If the next revolution is going to be capital intensive (ML at present) then you dont need to lock up engineering talent.

Cull all the staff you don't need, they aren't going to build your next competitor, they cant afford to.

The bets on moneybags-centric ML spending has many dead ends.

Draining capital into the wrong ones will be common and easy. Then the bubbles will burst and we will see how much raw capital and debt actually pay out.

How did both of these comments end up on the wrong article?

Reply on news.ycombinator.com